ADVANZ PHARMA GENERICS (UK) LIMITED exhibits a prompt average payment time of 28 days, indicating a strong tendency towards timely settlements. A significant majority, 57% of invoices, are paid within 30 days, establishing a consistent pattern of quick processing. While 43% of payments extend into the 31-60 day bracket, there is no trajectory towards excessive delays, as 0% of payments exceed 60 days.
Payment reliability is high, with no instances of payments exceeding 60 days and a minimal late payment rate of only 1%. Suppliers can predict a primary payment window, with 57% paid within 30 days and the remainder (43%) within 31-60 days. This distribution suggests a predictable, albeit sometimes extended, payment cycle, mitigating significant risk of unpredictably long delays.
ADVANZ PHARMA GENERICS presents a low payment risk profile for suppliers, characterized by an average 28-day payment time and a very low 1% late payment rate. Key decision factors for suppliers should be the high certainty of payment within 60 days and the strong likelihood of receiving payment within 30 days. No specific risk mitigation strategies for extreme payment default appear necessary based on this data, though aligning terms to account for the 30-60 day possibility is prudent.
| Reporting Period | Filing Date | Average Time to Pay (days) | Paid within 30 days | Paid 31-60 days | Paid after 60 days | Not Paid within Terms |
|---|---|---|---|---|---|---|
| 01 Jul 2024 - 31 Dec 2024 | 29 Jan 2025 | 28 | 57% | 43% | 0% | 1% |
| 01 Jan 2024 - 30 Jun 2024 | 29 Jul 2024 | 49 | 4% | 84% | 12% | 2% |
This information is as reported by the business, and responses are in their own words.
Standard payment terms
The Company follows a standard payment terms of "30 days end of the following month, in which the invoice is received". For Intercompany Vendor's the standard terms are "180 days from the date of invoice" The maximum contractual payment period (in days) - The maximum contractual payment terms for Intercompany Vendors is "180 days from the date of Invoice", for Vendors other than Intercompany vendors, the maximum contractual term is "30 days end of the following month" There have been no changes to the company standard terms during the reporting period.
Were there any changes to the standard payment terms in the reporting period?
No information available
Any other information about payment terms
NA
Maximum contractual payment period agreed
180
a) In case of any invoice disputes, the relevant department within the company availing the services is informed by email. The relevant department would then inform the vendor via email/phone of the nature of dispute and get it resolved. b) In case of disputes relating to services, the relevant department before approving the costs would inform the Vendor over an email. In case the invoice is considered to be correct, the same is internally approved and paid. c) For minor invoice errors, the Finance department may send an email directly to the relevant finance contact on Vendor side.
Has this business signed up to a code of conduct or standards on payment practices?
For example, signatories to The Prompt Payment Code must commit to paying 95% of their invoices within 60 days.
❌
Does this business offer e-invoicing in relation to qualifying contracts?
This is where suppliers can electronically submit and track invoices. It's not just allowing suppliers to email them an invoice.
❌
Does this business offer supply chain finance?
This is where a supplier who has submitted an invoice can be paid by a third-party finance provider earlier than the agreed payment date. The business would then pay the finance provider the invoiced sum.
❌
Under its payment practices and policies, can this business deduct sums from payments under qualifying contracts as a charge for remaining on a supplier list?
❌
During the reporting period, did the business deduct sums from payments as a charge for remaining on a supplier list?
No information available
ADVANZ PHARMA GENERICS (UK) LIMITED is an active private limited company operating within the pharmaceutical generics sector in the United Kingdom. Its company name indicates a specialisation in the development, manufacturing, and supply of generic pharmaceutical products.
The company was incorporated on 30 October 1992 and holds the company number 02760679. Its registered office is situated at Dashwood House, 69 Old Broad Street, London, United Kingdom, EC2M 1QS.
Companies of this type in the UK typically focus on producing and distributing medicines that are bioequivalent to branded drugs after their patents expire. This includes the marketing and supply of more affordable generic versions of established medications to healthcare providers and pharmacies across the UK market.